CD274 and non-small cell lung carcinoma: Yolchuyeva et al. [34–36] analyzed several models and feature selection approaches to predict survival and PD-L1 expression in NSCLC patients treated with immunotherapy, achieving an AUC of 0.69 for PD-L1 and a C-index of 0.59 for PFS.